In the United States, access to marijuana and its related products has been outlawed since passing the Controlled Substance Act (CSA) in 1970. Under this act, marijuana is classified as Schedule I substance and is considered to have a high potential for dependency and abuse as well as unaccepted medical use. From that time, multiple states have taken measures to legalize and decriminalize the use of marijuana. In June 2018, Epidiolex® (cannabidiol, CBD) was the first cannabis-derived drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe forms of epilepsy, Lennox-Gastaut syndrome, or Dravet syndrome. In December 2018, Farm Bill was significant progress in cannabis-related law by which hemp was removed from the definition of marijuana in the CSA. This paper provides an up-to-date overview of the legal status of cannabis-related aspects, including medical marijuana, home cultivation, patient registration, and hemp-derived CBD from the medical perspective in the United States.

中文翻译：

---

美国医用大麻和大麻二酚的现行法律地位

在美国，自 1970 年通过受控物质法案 (CSA) 以来，大麻及其相关产品的获取已被禁止。根据该法案，大麻被归类为附表 I 物质，被认为具有很高的依赖性和滥用潜力以及不被接受的医疗用途。从那时起，多个州已采取措施使大麻的使用合法化和非刑事化。2018 年 6 月，Epidiolex®（大麻二酚，CBD）是美国食品药品监督管理局（FDA）批准的第一种用于治疗严重癫痫、Lennox-Gastaut 综合征或 Dravet 综合征的大麻衍生药物。2018 年 12 月，《农场法案》是大麻相关法律的重大进展，根据该法案，大麻从 CSA 中的大麻定义中删除。